Ardelyx

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Ardelyx and other ETFs, options, and stocks.

About ARDX

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. 

CEO
Michael G. Raab
CEOMichael G. Raab
Employees
395
Employees395
Headquarters
Waltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded
2007
Founded2007
Employees
395
Employees395

ARDX Key Statistics

Market cap
1.42B
Market cap1.42B
Price-Earnings ratio
-24.74
Price-Earnings ratio-24.74
Dividend yield
Dividend yield
Average volume
3.66M
Average volume3.66M
High today
$5.95
High today$5.95
Low today
$5.66
Low today$5.66
Open price
$5.74
Open price$5.74
Volume
2.89M
Volume2.89M
52 Week high
$6.78
52 Week high$6.78
52 Week low
$3.21
52 Week low$3.21

Stock Snapshot

Ardelyx(ARDX) stock is priced at $5.92, giving the company a market capitalization of 1.42B. It carries a P/E multiple of -24.74.

As of 2025-11-15, Ardelyx(ARDX) stock has fluctuated between $5.66 and $5.95. The current price stands at $5.92, placing the stock +4.6% above today's low and -0.5% off the high.

The Ardelyx(ARDX)'s current trading volume is 2.89M, compared to an average daily volume of 3.66M.

During the past year, Ardelyx(ARDX) stock moved between $3.21 at its lowest and $6.78 at its peak.

During the past year, Ardelyx(ARDX) stock moved between $3.21 at its lowest and $6.78 at its peak.

ARDX News

Simply Wall St 1d
Does Real-World XPHOZAH Data Reveal a New Innovation Edge for Ardelyx?

Ardelyx, Inc. recently presented results from the first real-world study of XPHOZAH, its FDA-approved phosphate absorption inhibitor for adults with chronic kid...

Does Real-World XPHOZAH Data Reveal a New Innovation Edge for Ardelyx?

Analyst ratings

92%

of 12 ratings
Buy
91.7%
Hold
8.3%
Sell
0%

People also own

Based on the portfolios of people who own ARDX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.